Docu Liquid
NDC Package 17856-0771-2
Package Information
Docu Liquid (docusate sodium) liquids is a medication used to treat occasional constipation. This formulation utilizes a liquid delivery system. Marketed by Atlantic Biologicals Corp., this product is identified by NDC 17856-0771 and is authorized under FDA application M.
Identification & Billing
- RxCUI: 1248119 - docusate sodium 50 MG in 5 mL Oral Suspension
- RxCUI: 1248119 - docusate sodium 10 MG/ML Oral Suspension
- RxCUI: 1248119 - docusate sodium 100 MG per 10 ML Oral Suspension
- RxCUI: 1248119 - docusate sodium 150 MG per 15 ML Oral Suspension
- RxCUI: 1248119 - docusate sodium 50 MG per 5 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 17856 - Atlantic Biologicals Corp.
- 17856-0771 - Docu Liquid
- 17856-0771-2 - 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE / 10 mL in 1 CUP, UNIT-DOSE
- 17856-0771 - Docu Liquid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (17856-0771). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 17856-0771-2 identifies a specific commercial package of 72 cup, unit-dose in 1 box, unit-dose / 10 ml in 1 cup, unit-dose of Docu Liquid, a human over the counter drug labeled by Atlantic Biologicals Corp.. This liquid is formulated for oral use and contains docusate sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Atlantic Biologicals Corp. on August 01, 1997. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat occasional constipation. Some medications and conditions can make constipation more likely. Stool softeners such as docusate are often the first method used for preventing and treating this type of constipation. Docusate is often used when straining to have a bowel movement should be avoided (e.g., after a heart attack or surgery). Docusate is a stool softener. It works by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass.
How is this Atlantic Biologicals Corp. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 17856077102. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.